Ignite Creation Date:
2025-12-24 @ 12:11 PM
Ignite Modification Date:
2025-12-27 @ 10:09 PM
Study NCT ID:
NCT02410161
Status:
COMPLETED
Last Update Posted:
2019-02-18
First Post:
2015-03-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007662', 'term': 'Ketosis'}], 'ancestors': [{'id': 'D000138', 'term': 'Acidosis'}, {'id': 'D000137', 'term': 'Acid-Base Imbalance'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'stephen.cunnane@usherbrooke.ca', 'phone': '819-780-2220', 'title': 'Pr. Stephen Cunnane', 'phoneExt': '45670', 'organization': 'Université de Sherbrooke'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'Adverse event were collected during the 4-weeks supplementation of each participant', 'eventGroups': [{'id': 'EG000', 'title': 'Young Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).', 'otherNumAtRisk': 10, 'otherNumAffected': 0, 'seriousNumAtRisk': 10, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Old Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).', 'otherNumAtRisk': 10, 'otherNumAffected': 0, 'seriousNumAtRisk': 10, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Ketone Production', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Young Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}, {'id': 'OG001', 'title': 'Old Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}], 'classes': [{'categories': [{'measurements': [{'value': '217.71', 'spread': '24', 'groupId': 'OG000'}, {'value': '187.48', 'spread': '17', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'After 4 weeks', 'description': 'Total Ketone (acetoacetate + beta-hydroxybutyrate) concentration in plasma in average during the metabolic study day, measured hourly between 1 and 6h after breakfast', 'unitOfMeasure': 'µmol/L', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Plasma Glucose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Young Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}, {'id': 'OG001', 'title': 'Old Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}], 'classes': [{'categories': [{'measurements': [{'value': '4.75', 'spread': '0.13', 'groupId': 'OG000'}, {'value': '5.46', 'spread': '0.19', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'After 4 weeks', 'description': 'Glucose measured in plasma in average during the metabolic study day, measure hourly between 0 and 6 h after breakfast', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Plasma Triglycerides', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Young Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}, {'id': 'OG001', 'title': 'Old Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.97', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '1.81', 'spread': '0.29', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'After 4 weeks', 'description': 'Triglycerides measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Plasma Free Fatty Acids', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Young Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}, {'id': 'OG001', 'title': 'Old Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.48', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '0.55', 'spread': '0.04', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '4 weeks', 'description': 'Free fatty acids measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Insulin Concentration in Plasma', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Young Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}, {'id': 'OG001', 'title': 'Old Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}], 'classes': [{'categories': [{'measurements': [{'value': '10.48', 'spread': '1.48', 'groupId': 'OG000'}, {'value': '14.87', 'spread': '2.63', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'after 4 weeks', 'description': 'Insulin measured in plasma in average during the metabolic study day, measured hourly between 0 ans 6 h after breakfast', 'unitOfMeasure': 'µIU/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Young Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (ALA) (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}, {'id': 'FG001', 'title': 'Old Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Young Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}, {'id': 'BG001', 'title': 'Old Group 4 Week ALA Treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks\n\nalpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '25', 'spread': '2.8', 'groupId': 'BG000'}, {'value': '73', 'spread': '7', 'groupId': 'BG001'}, {'value': '52', 'spread': '25', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '13', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Canada', 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Dietary Supplement: alpha-linolenic acid-rich supplement'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-03', 'completionDateStruct': {'date': '2014-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-02-11', 'studyFirstSubmitDate': '2015-03-16', 'resultsFirstSubmitDate': '2017-09-12', 'studyFirstSubmitQcDate': '2015-04-01', 'lastUpdatePostDateStruct': {'date': '2019-02-18', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-02-11', 'studyFirstPostDateStruct': {'date': '2015-04-07', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-02-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2014-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Ketone Production', 'timeFrame': 'After 4 weeks', 'description': 'Total Ketone (acetoacetate + beta-hydroxybutyrate) concentration in plasma in average during the metabolic study day, measured hourly between 1 and 6h after breakfast'}], 'secondaryOutcomes': [{'measure': 'Plasma Glucose', 'timeFrame': 'After 4 weeks', 'description': 'Glucose measured in plasma in average during the metabolic study day, measure hourly between 0 and 6 h after breakfast'}, {'measure': 'Plasma Triglycerides', 'timeFrame': 'After 4 weeks', 'description': 'Triglycerides measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast'}, {'measure': 'Plasma Free Fatty Acids', 'timeFrame': '4 weeks', 'description': 'Free fatty acids measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast'}, {'measure': 'Insulin Concentration in Plasma', 'timeFrame': 'after 4 weeks', 'description': 'Insulin measured in plasma in average during the metabolic study day, measured hourly between 0 ans 6 h after breakfast'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['ketone', 'α-linolenic acid', 'flaxseed', 'aging', 'β-hydroxybutyrate', 'acetoacetate', 'omega-3 fatty acids', 'ketogenesis'], 'conditions': ['Healthy']}, 'descriptionModule': {'briefSummary': 'Background: As the main alternative fuel to glucose for the brain, increased plasma ketones could potentially help compensate for brain glucose hypometabolism occurring during aging. The precursor long-chain n-3 polyunsaturated fatty acid (PUFA), α-linolenic acid (ALA), is normally mostly β-oxidized and so could potentially be used to stimulate ketogenesis in humans.\n\nObjective: To compare the impact of an ALA-rich supplement on the ketogenic response in young and older healthy adults.\n\nDesign: Ten young and ten older adults will consume a flaxseed oil supplement providing 2 g/d of ALA for 4 weeks. Plasma ketones, free fatty acids, triglycerides, glucose and insulin will be measured over 6 h during two metabolic study days, one before and one at the end of the supplementation.\n\nHypothesis: ALA-rich supplement for 4 weeks will increase ketone production in both groups.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* aged between 18 and 30 or 65 years and more\n\nExclusion Criteria:\n\n* non smoker\n* pregnancy or breastfeeding\n* diabetes or insulin resistance\n* uncontrolled thyroid disease, hepatic or renal disease\n* uncontrolled high blood pressure\n* medical treatment influencing lipid or glucide metabolism\n* ongoing or past severe drug or alcohol abuse\n* dementia or psychiatric difficulties or depression\n* chronic immune condition or inflammation'}, 'identificationModule': {'nctId': 'NCT02410161', 'briefTitle': 'Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids', 'organization': {'class': 'OTHER', 'fullName': 'Université de Sherbrooke'}, 'officialTitle': 'Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma n-3 Polyunsaturated Fatty Acids in Young Compared to Older Adults', 'orgStudyIdInfo': {'id': '2014-389'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '4 week ALA treatment', 'description': 'Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks', 'interventionNames': ['Dietary Supplement: alpha-linolenic acid-rich supplement']}], 'interventions': [{'name': 'alpha-linolenic acid-rich supplement', 'type': 'DIETARY_SUPPLEMENT', 'description': 'each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).', 'armGroupLabels': ['4 week ALA treatment']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Stephen Cunnane, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Université de Sherbrooke'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Université de Sherbrooke', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}